Skip to content

US · BDRX · BIOTECHNOLOGY

Biodexa Pharmaceuticals Plc (BDRX) intrinsic value and stock valuation

$1.88as of 2026-11-21 · Mkt cap 1.19M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Biodexa Pharmaceuticals Plc DCF and intrinsic value

InvestorsCraft values BDRX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from BDRX’s statements →

Biodexa Pharmaceuticals Plc Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Cardiff, WA CF10 4DQ biodexapharma.com

How the business is doing

Fiscal 2012–2025, USD

Revenue
$0.00
20122025
Net income
-$-6.24M
20122025
Free cash flow
-$-5.4M
20122025
Total equity
$11.4M+11.1% 5y CAGRd
20122025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2012–2025, USD
20252024202320222021
Revenue$0.00$0.00$380K$700K$580K
Operating income-$-8.27M-$-9.2M-$-8.01M-$-8.93M-$-7M
Net income-$-6.24M-$-5.73M-$-7.08M-$-7.66M-$-5.46M
EPSd-$-312M————
Operating cash flow-$-5.39M-$-12.26M-$-6.83M-$-7.05M-$-6.01M
Capital expenditure-$0.00-$-770K-$-260K-$-60K-$-320K
Free cash flow-$-5.4M-$-13.04M-$-7.09M-$-7.11M-$-6.33M
Total assets$18.2M$14.8M$10.5M$5.53M$12.9M
Total debt$60K$730K$460K$620K$770K
Net debt-$-8.46M-$-940K-$-5.51M-$-2.21M-$-9.29M
Total equity$11.4M$8.32M$4.68M$3.16M$10.5M
Cash and short-term investments$8.52M$1.67M$5.97M$2.84M$10.1M
Income statement
20252024202320222021
Revenue$0.00$0.00$380K$700K$580K
Cost of revenue$180K$5.44M$4.07M$5.11M$4.65M
Gross profit-$-180K-$-5.44M-$-3.69M-$-4.41M-$-4.08M
Research and development expenses$3.73M$5.44M$4.07M$5.11M$4.65M
Selling, general and administrative expenses$4.84M$3.79M$4.34M$4.54M$2.95M
Other expenses-$-480K-$-5.47M-$-4.08M-$-5.13M-$-4.68M
Operating expenses$8.08M$3.76M$4.33M$4.52M$2.92M
Cost and expenses$8.27M$9.2M$8.39M$9.63M$7.58M
Interest income$90K$0.00$80K$30K$0.00
Interest expense$70K$20K$40K$50K$40K
Depreciation and amortization$180K$120K$280K$170K$400K
Ebitda-$-8.08M-$-9.08M-$-7.16M-$-8.26M-$-5.66M
Operating income-$-8.27M-$-9.2M-$-8.01M-$-8.93M-$-7M
Total other income/expenses, net$1.92M$3.22M$530K$440K$890K
Income before tax-$-6.35M-$-5.98M-$-7.49M-$-8.49M-$-6.11M
Income tax expense-$-100K-$-250K-$-410K-$-830K-$-650K
Net income-$-6.24M-$-5.73M-$-7.08M-$-7.66M-$-5.46M
Weighted average shares outstanding$20K$0.00$0.00$0.00$0.00
Weighted average diluted shares outstanding$20K$0.00$0.00$0.00$0.00
Balance sheet
20252024202320222021
Cash and short-term investments$8.52M$1.67M$5.97M$2.84M$10.1M
Net receivables$220K$710K$700K$330K$30K
Inventory$0.00$0.00-$-700K$0.00$0.00
Total current assets$12.4M$8.81M$7.03M$4.69M$11.8M
Property, plant and equipment, net$90K$320K$570K$830K$1.15M
Goodwill and intangible assets$5.64M$5.65M$2.94M$10K$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$5.73M$5.97M$3.51M$840K$1.15M
Total assets$18.2M$14.8M$10.5M$5.53M$12.9M
Accounts payable$100K$710K$310K$340K$480K
Short-term debt$60K$610K$170K$160K$150K
Deferred revenue$570K$1.47M$0.00$200K$0.00
Total current liabilities$6.12M$5.03M$5.57M$1.9M$1.84M
Long-term debt$0.00$120K$290K$460K$620K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$640K$1.42M$290K$460K$620K
Capital lease obligations$60K$730K$460K$620K$770K
Total liabilities$6.76M$6.46M$5.86M$2.36M$2.46M
Common stock$14.1M$6.69M$1.19M$110K$100K
Retained earnings-$-102.62M-$-150.42M-$-144.77M-$-135.34M-$-127.8M
Accumulated other comprehensive income (loss)$1.19M$53M$61.5M$53M$53M
Total equity$11.4M$8.32M$4.68M$3.16M$10.5M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$60K$730K$460K$620K$770K
Net debt-$-8.46M-$-940K-$-5.51M-$-2.21M-$-9.29M
Cash flow statement
20252024202320222021
Net income-$-6.38M-$-5.73M-$-7.08M-$-7.66M-$-5.46M
Depreciation and amortization$180K$250K$280K$340K$400K
Stock-based compensation$170K$280K$30K$120K$90K
Change in working capital$1.68M-$-3.74M-$-50K$520K-$-620K
Accounts receivable$2.57M-$-5.97M$360K$10K-$-490K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-890K$0.00$0.00$0.00$0.00
Net cash provided by operating activities-$-5.39M-$-12.26M-$-6.83M-$-7.05M-$-6.01M
Investments in property, plant and equipment-$-680K-$-10K-$-30K-$-60K-$-320K
Acquisitions, net$20K$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-660K-$-600K-$-270K-$-220K-$-280K
Common stock issued$13.5M$8.31M$10.4M$240K$9.04M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$12.8M$8.56M$10.2M$50K$8.8M
Net change in cash$6.97M-$-4.3M$3.13M-$-7.22M$2.51M
Cash at end of period$8.52M$1.67M$5.97M$2.84M$10.1M
Operating cash flow-$-5.39M-$-12.26M-$-6.83M-$-7.05M-$-6.01M
Capital expenditure-$0.00-$-770K-$-260K-$-60K-$-320K
Free cash flow-$-5.4M-$-13.04M-$-7.09M-$-7.11M-$-6.33M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Biodexa Pharmaceuticals Plc

        Biodexa Pharmaceuticals Plc, a biopharmaceutical company in the clinical development stage, is dedicated to advancing a diverse portfolio of products. Founded in 2000 and headquartered in Cardiff, United Kingdom, the company was formerly known as Midatech Pharma plc until its rebranding in March 2023. Its research and development efforts are focused on addressing significant unmet medical needs, including familial adenomatous polyposis, non-muscle invasive bladder cancer, Type 1 diabetes, and a spectrum of rare or orphan brain cancers. The company's primary drug candidate, Tolimidone, a selective activator of the lyn kinase enzyme, is currently undergoing Phase II clinical trials for the management of Type 1 diabetes. Additionally, Biodexa is progressing MTX110 through Phase I studies as an investigational treatment targeting specific challenging brain malignancies such as diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma. Beyond its direct drug pipeline, Biodexa Pharmaceuticals also provides a suite of advanced drug delivery platforms designed to optimize therapeutic efficacy. These include Q-Sphera, a microtechnology utilizing polymer microspheres for controlled, sustained release of medications; MidaSolve, an oligosaccharide nanotechnology that facilitates the solubilization of drugs, enabling their direct and localized administration into tumor sites; and MidaCore, which employs gold nanoparticles for precise targeting of diseased areas, allowing for the delivery of either chemotherapeutic or immunotherapeutic agents. The company has established strategic collaboration agreements with pharmaceutical industry leaders Janssen and Melior.

        CEO
        Stephen Anthony Stamp
        Employees
        11
        Beta
        1.21

        Explore

        Frequently asked questions

        What is the intrinsic value of Biodexa Pharmaceuticals Plc (BDRX)?

        InvestorsCraft does not currently publish an intrinsic value for BDRX. How the IC value is calculated.

        Is BDRX undervalued?

        InvestorsCraft does not publish an undervaluation signal for BDRX at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.